Cargando…
Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science
Cardiovascular disease is the number one cause of death and disability worldwide. While substantial gains have been made in reducing cardiovascular mortality, future projections suggest that we have reached a nadir and may be at an inflection point, given the rising tide of obesity and diabetes. Eva...
Autores principales: | German, Charles Amir, Shapiro, Michael David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387892/ https://www.ncbi.nlm.nih.gov/pubmed/32742310 http://dx.doi.org/10.15420/ecr.2019.18 |
Ejemplares similares
-
The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
por: Gabani, Mohanad, et al.
Publicado: (2023) -
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control
por: Rikhi, Rishi, et al.
Publicado: (2023) -
Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project
por: Santi, Ricardo Lopez, et al.
Publicado: (2021) -
Novel Biomarkers for Atherosclerotic Disease: Advances in Cardiovascular Risk Assessment
por: Jigoranu, Raul-Alexandru, et al.
Publicado: (2023) -
Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
por: Bi, Lei, et al.
Publicado: (2022)